| Closing Price ($) | Shares Out (MM) | Market Cap ($MM) |
| $2.93 | 22 | $63 |
| 10-Q | 2019-09-30 | Quarter: 2019-09-30 |
| 10-Q | 2019-06-30 | Quarter: 2019-06-30 |
| 10-Q | 2019-03-31 | Quarter: 2019-03-31 |
| 10-K | 2018-12-31 | Annual: 2018-12-31 |
| 10-Q | 2018-09-30 | Quarter: 2018-09-30 |
| 10-Q | 2018-06-30 | Quarter: 2018-06-30 |
| 10-Q | 2018-03-31 | Quarter: 2018-03-31 |
| 10-K | 2017-12-31 | Annual: 2017-12-31 |
| 10-Q | 2017-09-30 | Quarter: 2017-09-30 |
| 10-Q | 2017-06-30 | Quarter: 2017-06-30 |
| 10-Q | 2017-03-31 | Quarter: 2017-03-31 |
| 10-K | 2016-12-31 | Annual: 2016-12-31 |
| 8-K | 2019-11-05 | Earnings, Exhibits |
| 8-K | 2019-08-06 | Earnings, Exhibits |
| 8-K | 2019-06-04 | Other Events, Exhibits |
| 8-K | 2019-04-30 | Earnings, Officers, Shareholder Vote, Exhibits |
| 8-K | 2019-04-19 | Officers |
| 8-K | 2019-04-16 | Other Events, Exhibits |
| 8-K | 2019-04-04 | Enter Agreement, Other Events, Exhibits |
| 8-K | 2019-04-04 | Other Events, Exhibits |
| 8-K | 2019-04-02 | Other Events, Exhibits |
| 8-K | 2019-03-21 | Officers |
| 8-K | 2019-03-19 | Enter Agreement, Other Events, Exhibits |
| 8-K | 2019-03-19 | Other Events, Exhibits |
| 8-K | 2019-03-18 | Other Events, Exhibits |
| 8-K | 2019-03-14 | Regulation FD, Exhibits |
| 8-K | 2019-03-08 | Other Events, Exhibits |
| 8-K | 2019-03-07 | Earnings, Exhibits |
| 8-K | 2018-11-28 | Officers, Regulation FD, Exhibits |
| 8-K | 2018-11-02 | Earnings, Exhibits |
| 8-K | 2018-10-24 | Enter Agreement, Shareholder Rights, Exhibits |
| 8-K | 2018-10-16 | Enter Agreement, Off-BS Arrangement, Regulation FD, Exhibits |
| 8-K | 2018-09-04 | Regulation FD, Exhibits |
| 8-K | 2018-08-07 | Earnings, Exhibits |
| 8-K | 2018-05-01 | Shareholder Vote |
| 8-K | 2018-04-26 | Other Events, Exhibits |
| 8-K | 2018-01-12 | Enter Agreement, Other Events, Exhibits |
| Comps ($'000 TTM) | Market Cap | Assets | Liabilities | Revenue | Gross Profit | Net Income | EBITDA | EV |
|---|---|---|---|---|---|---|---|---|
| Arcturus Therapeutics (ARCT) | 53,595 | 44,419 | 38,065 | 4,350 | 0 | -6,884 | -6,712 | 32,213 |
| All Soft Gels (ASG) | 111,547 | 56 | 716 | 136 | 55 | -1,463 | -1,368 | 111,740 |
| Mercantile Bankshares (MRBK) | 115,326 | 1,055,906 | 941,527 | 0 | 0 | 9,119 | 29,812 | 84,696 |
| Synlogic (SYBX) | 282,623 | 214,945 | 34,122 | 2,600 | 0 | -47,969 | -46,020 | 153,623 |
| Inflarx (IFRX) | 159,214 | 7,824 | 0 | 0 | 0 | 0 | -0 | |
| Cellect Biotechnology (APOP) | 345,599 | 20,638 | 0 | 0 | 0 | 0 | 345,262 | |
| Aquabounty Technologies (AQB) | 61,340 | 36,775 | 7,056 | 158 | 23 | -11,942 | -10,756 | 55,565 |
| US Gold (USAU) | 21,724 | 8,772 | 384 | 0 | 0 | -7,583 | -7,147 | 18,185 |
| 1st Franklin Financial (FFC) | 3,210 | 833,128 | 581,983 | 0 | 0 | 58,119 | 81,934 | -17,598 |
| Pioneer (PIO) | ||||||||
| Pet DRx (VETS) | ||||||||
| TH Merger Company (CSA) | 1,667,207 | 692,104 | 529,844 | 0 | 0 | 0 | 0 | 1,650,478 |
| Delphi Financial Group (DFP) | 8,634,408 | 6,854,525 | 0 | 0 | 0 | 0 | -0 | |
| Alberto-Culver (ACV) | ||||||||
| Pelican Financial (PFI) | ||||||||
| Apollo Investment (AINV) | ||||||||
| Dusa Pharmaceuticals (DUSA) | 551,168 | 41,655 | 11,248 | 0 | 29,530 | 426 | 869 | 522,432 |
| Imagistics (IGI) | ||||||||
| Syncora Holdings (SCA) |
| Balance Sheet ($'000) | 2017-03-31 | 2017-06-30 | 2017-09-30 | 2017-12-31 | 2018-03-31 | 2018-06-30 | 2018-09-30 | 2018-12-31 | 2019-03-31 | 2019-06-30 |
| Cash | 25,473 | 7,991 | 4,718 | 493 | 6,839 | 3,519 | 1,031 | 2,990 | 7,630 | 10,401 |
| Accounts Receivable | ||||||||||
| Inventory | 101 | 78 | 78 | 172 | 125 | 82 | 73 | 76 | 159 | 210 |
| PP&E | 3,545 | 19,329 | 21,000 | 23,360 | 25,179 | 25,371 | 26,063 | 25,973 | 26,506 | 27,515 |
| Assets | 28,549 | 26,908 | 25,296 | 23,732 | 31,488 | 28,260 | 26,043 | 27,671 | 33,030 | 36,775 |
| Accounts Payable | 267 | 367 | 491 | 1,090 | 1,077 | 526 | 719 | 367 | 279 | 1,096 |
| Long-Term Debt | ||||||||||
| Liabilities | 3,590 | 3,955 | 4,718 | 5,751 | 5,154 | 4,160 | 4,514 | 4,437 | 5,473 | 7,056 |
| Stockholders' Equity | 24,959 | 22,953 | 20,578 | 17,981 | 26,334 | 24,100 | 21,529 | 23,234 | 27,556 | 29,718 |
| Income Statement ($'000) | 2017-03-31 | 2017-06-30 | 2017-09-30 | 2017-12-31 | 2018-03-31 | 2018-06-30 | 2018-09-30 | 2018-12-31 | 2019-03-31 | 2019-06-30 |
| Revenue | 53 | 0 | 0 | 19 | 48 | 11 | 7 | 98 | 42 | |
| Cost of Revenue | 47 | 9 | 6 | 82 | 39 | |||||
| Gross Profit | 1 | 2 | 1 | 16 | 3 | |||||
| R&D | 720 | 936 | 861 | 855 | 978 | 881 | 805 | 795 | 663 | 813 |
| SG&A | 1,329 | 1,153 | 1,578 | 1,802 | 1,469 | 1,904 | 1,917 | 1,623 | 2,108 | 3,210 |
| Tax | ||||||||||
| Net Income | -2,056 | -2,093 | -2,446 | -2,663 | -2,450 | -2,781 | -2,727 | -2,424 | -2,764 | -4,027 |
| Cash Flow ($'000) | 2017-03-31 | 2017-06-30 | 2017-09-30 | 2017-12-31 | 2018-03-31 | 2018-06-30 | 2018-09-30 | 2018-12-31 | 2019-03-31 | 2019-06-30 |
| Cash Operating | -2,504 | -1,893 | -2,279 | -2,425 | -2,467 | -2,867 | -2,135 | -2,348 | -2,133 | -3,073 |
| Cash Investing | -457 | -15,737 | -1,041 | -1,811 | -2,033 | -985 | -336 | -728 | -456 | -461 |
| Cash Financing | 25,110 | 152 | -12 | -12 | 10,852 | 547 | -15 | 5,064 | 7,227 | 6,292 |